Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31673865 | 1.00 | GLP1R (1.00) | GLP1R | |
| SCHEMBL6305960 | 0.85 | GLP1R (0.74) | GLP1R | |
| SCHEMBL6311574 | 0.82 | GLP1R (0.69) | GLP1R | |
| SCHEMBL6307213 | 0.78 | GLP1R (1.00) | GLP1R | |
| SCHEMBL6304253 | 0.78 | GLP1R (1.00) | GLP1R | |
| SCHEMBL6311925 | 0.77 | GLP1R (0.91) | GLP1R | |
| SCHEMBL6305727 | 0.76 | GLP1R (0.73) | GLP1R | |
| SCHEMBL6311083 | 0.76 | GLP1R (0.60) | GLP1R | |
| SCHEMBL6306869 | 0.75 | GLP1R (0.72) | GLP1R | |
| SCHEMBL6307043 | 0.74 | GLP1R (0.68) | GLP1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016034708-A1 | USE OF A QUINOXALINE DERIVATIVE IN AN IMAGING METHOD | EBERHARD KARLS UNIVERSITAET TUEBINGEN MEDIZINISCHE FAKULTAET (DE) | 2016-03-10 | — | — | WO | claimed |
| US-6927214-B1 | Non-peptide GLP-1 agonists | NOVO NORDISK A/S (DK) | 2005-08-09 | — | — | US | claimed |
| US-12220444-B2 | Treatment of hyperinsulinemic hypoglycemia with GLP-1 antagonist exendin(9-39) | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2025-02-11 | — | — | US | disclosed |
| US-20230346890-A1 | TREATMENT OF POST-BARIATRIC HYPOGLYCEMIA WITH GLP-1 ANTAGONISTS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2023-11-02 | — | — | US | disclosed |
| US-11622995-B2 | Treatment of post-bariatric hypoglycemia with GLP-1 antagonists | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2023-04-11 | — | — | US | disclosed |
| EP-3978011-A1 | TREATMENT OF POST-BARIATRIC HYPOGLYCEMIA WITH GLP-1 ANTAGONISTS | The Board of Trustees of the Leland Stanford Junior University (US) | 2022-04-06 | — | — | EP | disclosed |
| US-20210346509-A1 | GLP-1 Receptor Ligand Moiety Conjugated Oligonucleotides and Uses Thereof | ASTRAZENECA AB (SE) | 2021-11-11 | — | — | US | disclosed |
| US-20210290731-A1 | TREATMENT OF POST-BARIATRIC HYPOGLYCEMIA WITH GLP-1 ANTAGONISTS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2021-09-23 | — | — | US | disclosed |
| US-10993992-B2 | Treatment of post-bariatric hypoglycemia with GLP-1 antagonists | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2021-05-04 | — | — | US | disclosed |
| US-20200276272-A1 | TREATMENT OF POST-BARIATRIC HYPOGLYCEMIA WITH GLP-1 ANTAGONISTS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2020-09-03 | — | — | US | disclosed |
| US-20200268898-A1 | GLP-1 RECEPTOR LIGAND MOIETY CONJUGATED OLIGONUCLEOTIDES AND USES THEREOF | IONIS PHARMACEUTICALS, INC. | 2020-08-27 | — | — | US | disclosed |
| EP-2555791-B1 | METHODS FOR TREATING DISORDERS OF THE GASTROINTESTINAL TRACT USING A GLP-1 AGONIST | SINAI HEALTH SYS (CA) | 2017-11-01 | — | — | EP | disclosed |
| WO-2016191394-A1 | TREATMENT OF POST-BARIATRIC HYPOGLYCEMIA WITH GLP-1 ANTAGONISTS | THE BOT OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2016-12-01 | — | — | WO | disclosed |
| WO-2016034708-A1 | USE OF A QUINOXALINE DERIVATIVE IN AN IMAGING METHOD | EBERHARD KARLS UNIVERSITAET TUEBINGEN MEDIZINISCHE FAKULTAET (DE) | 2016-03-10 | — | — | WO | disclosed |
| US-9168288-B2 | Methods for treating disorders of the gastrointestinal tract using a GLP-1 agonist | MOUNT SINAI HOSPITAL (CA) | 2015-10-27 | — | — | US | disclosed |
| US-20130053316-A1 | Methods for Treating Disorders of the Gastrointestinal Tract Using a GLP-1 Agonist | MOUNT SINAI HOSPITAL (CA) | 2013-02-28 | — | — | US | disclosed |
| EP-2555791-A1 | METHODS FOR TREATING DISORDERS OF THE GASTROINTESTINAL TRACT USING A GLP-1 AGONIST | Mt. Sinai Hospital (CA) | 2013-02-13 | — | — | EP | disclosed |
| WO-2011123943-A1 | METHODS FOR TREATING DISORDERS OF THE GASTROINTESTINAL TRACT USING A GLP-1 AGONIST | MOUNT SINAI HOSPITAL (CA) | 2011-10-13 | — | — | WO | disclosed |
| WO-2011122815-A2 | NOVEL QUINOXALINE DERIVATIVES | DONG-A PHARM.CO.,LTD. (KR) | 2011-10-06 | — | — | WO | disclosed |
| US-6927214-B1 | Non-peptide GLP-1 agonists | NOVO NORDISK A/S (DK) | 2005-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210346509-A1 | GLP-1 Receptor Ligand Moiety Conjugated Oligonucleotides and Uses Thereof | GLP1R, GIPR, GRPR | GLP1R 1/4885 |
| US-20200268898-A1 | GLP-1 RECEPTOR LIGAND MOIETY CONJUGATED OLIGONUCLEOTIDES AND USES THEREOF | GLP1R, GIPR, GRPR | GLP1R 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.